Transcatheter Tricuspid Valve Implantation of NaviGate Bioprosthesis in a Preclinical Model

• DOI: 10.1016/j.jacbts.2017.08.003
• Publication Date: 2018-01-24T19:06:29Z
• Authors: Jose L. Navia; Samir Kapadia; Haytham Elgharably; Gabriel Maluenda; Krzysztof Bartuś; Cristian Baeza; Rajesh K. Nair; Josep Rodés-Cabau; Cesare Beghi; Rodolfo C. Quijano
• Keywords: PRECLINICAL RESEARCH; 03 medical and health sciences; 0302 clinical medicine; RC666-701; Diseases of the circulatory (Cardiovascular) system; NaviGate bioprosthesis; transcatheter replacement; NaviGate bioprosthesis; preclinical model; transcatheter replacement; tricuspid valve; Cardiology and Cardiovascular Medicine; tricuspid valve; preclinical model; 3. Good health

Patients with isolated functional or recurrent tricuspid regurgitation are often denied surgery because they considered to be at high risk. Transcatheter valve therapy provides a less invasive alternative for associated right heart failure. We have evaluated the feasibility of transcatheter implantation NaviGate valved stent in long-term swine model. The was successfully implanted through transjugular and transatrial approaches on beating excellent hemodynamic performance. No conduction disturbance coronary obstruction observed. This technology could provide an treatment patients who surgical risk severe compromised ventricular function.